Medigene (ETR:MDG1) Shares Up 5.3%

Medigene AG (ETR:MDG1)’s stock price traded up 5.3% during trading on Thursday . The stock traded as high as €1.20 ($1.30) and last traded at €1.20 ($1.30). 8,069 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 306,207 shares. The stock had previously closed at €1.14 ($1.23).

Medigene Stock Performance

The company has a debt-to-equity ratio of 14.00, a current ratio of 2.53 and a quick ratio of 5.85. The stock has a market cap of $35.23 million, a price-to-earnings ratio of -1.90, a PEG ratio of 7.12 and a beta of 0.91. The firm has a fifty day moving average of €1.28 and a 200 day moving average of €1.52.

About Medigene

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.